青少年中的大麻素激增症候群:一个单一机构的案例系列
Claudia Vega Castellvi1, Natalie F Jennings1, Melissa Clemente Fabrega1
1Nicklaus Children's Hospital, Miami, FL.
Pediatric emergency care
|February 26, 2026
概括
大麻素高症候群 (CHS) 是由于经常使用大麻而引起的严重吐障碍. 这项研究研究了儿童的CHS,重点关注治疗,医疗保健使用和相关条件.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 毒理学 毒理学 毒理学
- 大麻研究 大麻研究
背景情况:
- 大麻素高症候群 (CHS) 是一种以反复恶心和吐为特征的疾病.
- CHS与长期,频繁的大麻消费有关.
- CHS往往被诊断不足,导致严重的医疗负担.
研究的目的:
- 为了呈现一个大型的儿科CHS病例系列.
- 分析儿童中CHS治疗疗效.
- 评估儿科CHS病例中的医疗保健利用率和并发症.
主要方法:
- 追溯案例系列分析.
- 包括被诊断患有CHS的儿科患者.
- 收集有关人口统计,大麻使用模式,症状,治疗,医疗保健访问和并发症的数据.
主要成果:
- 儿科CHS队列的详细特征.
- 评估各种治疗策略及其有效性.
- 量化医疗保健利用率和相关的健康问题.
结论:
- 儿科的CHS需要更大的临床意识,以便及时诊断.
- 对于儿科CHS的有效管理策略需要进一步研究.
- 了解并发症对于儿科CHS患者的综合护理至关重要.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
856
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
856
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
684
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
684
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
976
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
976
Pathophysiology of Vomiting
3.4K
Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
3.4K
Drug Toxicity: Risk factors
59
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
59
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
741
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
741


